ALSO IN THIS MONTH'S ISSUE

• Strategizing The Scale-Up Of Cell Therapy Manufacturing Capacity

  Mike Blankenstein, VP of patient supply operations AT Adaptimmune, discusses the company’s strategy for its cell therapy manufacturing facility and scaling up capacity.

• A Quick Transition To Late-Stage Clinical Trials

  “Moving into Phase 3 not only expands the resources you need internally, but some things require a much larger amount of capital, and often a public listing so you can raise larger amounts of money,” says Eric Dobmeier, president and CEO, Chinook Therapeutics.

• New DSCSA Compliance Blueprint Includes FDA & Industry Input

  As we approach the final phase of a 10-year rollout of the Drug Supply Chain Security Act (DSCSA), which aims to create a more secure, interoperable drug supply chain in the U.S., pharma manufacturers, distributors, and pharmacies must all ensure they are ready for its full implementation starting on Nov. 27, 2023.

• Key Questions To Ask When Entering A Pharma Partnership

  Before entering a partnership, executives need to ask themselves and their prospective partners’ key questions in the following five areas: